Loading company…
Slayback Pharma develops and markets specialty pharmaceutical products for niche patient populations, with over 30 brands.
The company's products are marketed in over 50 countries across areas such as Allergy, Oncology and Respiratory, mainly to healthcare providers and specialty pharmacies. Founded in 2011 in Princeton, US, it was acquired by Azurity Pharmaceuticals from KKR and Everstone Capital Partners in September 2023. Its most recent deal, a Series B round on September 27, 2023, raised USD 50.00 mn, the total amount raised to date.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in